Ribon Therapeutics
↗Cambridge, MA, United States
Ribon Therapeutics was a clinical-stage biotechnology company focused on the discovery and development of first-in-class small molecule inhibitors designed to block fundamental survival mechanisms of cancer cells under stress. The company was leveraging its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform to develop selective inhibitors targeting NAD+-utilizing enzymes, beginning with PARP (Poly ADP-Ribose Polymerase) inhibitors. Founded in 2015 and headquartered in Cambridge, Massachusetts, Ribon was backed by major pharmaceutical companies including Pfizer, AbbVie, Bristol Myers Squibb, Johnson & Johnson, Novartis, and Takeda. The company permanently ceased operations on August 2, 2024, after discontinuing all material operations and conducting an online asset auction in May 2024.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue (clinical stage)
Founded:2015
Ownership:private
Status:shutdown
FUNDING
Stage:Series C/D
Total Raised:$209M
Investors:Deerfield Management, U.S. Venture Partners, AbbVie Ventures, Bristol Myers Squibb, Johnson & Johnson Innovation (JJDC), Novartis Venture Fund, Takeda Ventures, The Column Group, Avego BioScience Capital, GV (Google Ventures), Monashee Investment Management, Peregrine Ventures, Osage University Partners, Euclidean Capital, Pfizer (equity investment January 2023)
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2 (RBN-2397 in combination trials)
Modalities:Small molecule, PARP inhibitors
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Ono Pharmaceutical: Exclusive license agreement for RBN-2397 (atamparib) development and commercialization in Japan, South Korea, Taiwan, and ASEAN countries (Feb 2021), Merck: RBN-2397 development in combination with Keytruda (pembrolizumab) for squamous cell lung cancer, Nerviano Medical Sciences: Post-closure: Nerviano acquired atamparib (RBN-2397) from Ribon assets in November 2024 to advance Phase 2 development
COMPETITION
Position:Niche Player (now closed)
Competitors:Repligen Corporation, Arcus Biosciences, Jounce Therapeutics, Syndax Pharmaceuticals, Artisan Therapeutics, Other PARP inhibitor developers
LEADERSHIP
Key Executives:
Prakash Raman, Ph.D. - CEO
Victoria Richon, Ph.D. - Founding President / R&D Adviser
Hiep Tran - Chief Scientific Officer / Co-Founder
Scientific Founders:W. Lee Kraus (Founder), Hiep Tran (Co-Founder)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ribon Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.